<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901757</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MERO-102</org_study_id>
    <nct_id>NCT01901757</nct_id>
  </id_info>
  <brief_title>Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of HCP1201 Tablet in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of food in healthy male volunteers who receive HCP1201 tablet in&#xD;
      fed versus fasted condition&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, single-dose crossover study to evaluate the effect of food on the&#xD;
      pharmacokinetics of HCP1201 tablet in healthy volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin, rosuvastatin Cmax, AUClast</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin Tmax</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin T1/2</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin AUCinf</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin CL/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, rosuvastatin Vd/F</measure>
    <time_frame>pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HCP1201, Fasted followed by fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1201 dosing in the fasted state followed by fed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP1201, Fed followed by fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1201 dosing in the fed state followed by fasted dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1201, Fasted followed by fed</intervention_name>
    <description>There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.</description>
    <arm_group_label>HCP1201, Fasted followed by fed</arm_group_label>
    <arm_group_label>HCP1201, Fed followed by fasted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1201, Fed followed by fasted</intervention_name>
    <description>There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.</description>
    <arm_group_label>HCP1201, Fasted followed by fed</arm_group_label>
    <arm_group_label>HCP1201, Fed followed by fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male volunteer, age 20~55 years&#xD;
&#xD;
          2. The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2&#xD;
&#xD;
          3. Subject who has the ability to comprehend the study objectives, contents and the&#xD;
             property of the study drug before participating in the trial&#xD;
&#xD;
          4. Subject who has the ability and willingness to participate the whole period of trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of medical history or a concurrent disease that may interfere with treatment&#xD;
             and safety assessment or completion of this clinical study, including clinically&#xD;
             significant disorders in kidney, liver, cardiovascular system, respiratory system,&#xD;
             endocrine system, or neuropsychiatric system.&#xD;
&#xD;
          2. Glomerular filtration rate is under 60ml/min which is calculated by serum creatinine&#xD;
             value.&#xD;
&#xD;
          3. Liver enzyme (AST, ALT) level exceeds the maximum normal range more than one and a&#xD;
             half times.&#xD;
&#xD;
          4. Systolic Blood Pressure: lower than 90mmHg or higher than 150mmHg, Diastolic Blood&#xD;
             Pressure: lower than 60mmHg or higher than 100mmHg&#xD;
&#xD;
          5. History of relevant drug allergies or clinically significant hypersensitivity&#xD;
             reaction.&#xD;
&#xD;
          6. History of drug abuse or positive drug screening.&#xD;
&#xD;
          7. Participation in other drug studies within 60days prior to the drug administration.&#xD;
&#xD;
          8. Whole blood donation within 60 days, blood component donation within 30 days or who&#xD;
             got transfusion within 30days.&#xD;
&#xD;
          9. Subjects who took prescription drugs within 14 days from the patient screening or&#xD;
             non-prescription medicine within 7 days which can affect the result of this clinical&#xD;
             trial (acceptable according to the investigator's judgement)&#xD;
&#xD;
         10. Subjects who took medicines(e.g. proton pump inhibitor, rifampicin, oriental&#xD;
             medicines, etc.) within 30days that can affect absorption, distribution, metabolism,&#xD;
             elimination of metformin/rosuvastatin.&#xD;
&#xD;
         11. Intake of more than 140g of alcohol per week or who can't abstain from alcohol during&#xD;
             the trial.&#xD;
&#xD;
         12. Subjects who smoke more than 10 cigarettes per day or who can't quit smoking during&#xD;
             the trial.&#xD;
&#xD;
         13. Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C virus(HCV)&#xD;
             or anti-Human immunodeficiency virus(HIV).&#xD;
&#xD;
         14. Genetic myopathic disorder or related family history, medical history of myopathic&#xD;
             disorder caused by medication.&#xD;
&#xD;
         15. Clinically inappropriate laboratory test result.&#xD;
&#xD;
         16. Clinically inappropriate electrocardiogram result.&#xD;
&#xD;
         17. Subjects who judged ineligible by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Ryul Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 7, 2013</study_first_submitted>
  <study_first_submitted_qc>July 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

